<DOC>
	<DOCNO>NCT00909636</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics escalate multiple dos ABT-333 tablet formulation healthy adult subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Multiple Ascending Doses ABT-333 Tablet</brief_title>
	<detailed_description />
	<criteria>overall healthy subject age 18 55 year old ; female , subject must either postmenopausal least 2 year surgically sterile ; female must negative result pregnancy test perform ; male , subject must surgically sterile practice least 1 follow method birth control : partner ( ) use IUD , partner ( ) use oral , injected implant method hormonal contraceptive , subject and/or partner ( ) use doublebarrier method ; Body Mass Index 18 29 , inclusive history significant sensitivity drug ; positive test HAV IgM , HBsAg , HCV Ab HIV Ab ; history gastrointestinal issue procedure ; history seizure , diabetes cancer ( except basal cell carcinoma ) ; clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder ; use tobacco nicotinecontaining product 6month period prior study drug administration ; donation loss 550 mL blood volume receipt transfusion blood product within 8 week prior study drug administration ; clinically significant abnormal screen laboratory analysis ECGs : ALT &gt; ULN , AST &gt; ULN , ECG QTcF &gt; 450 msec female &gt; 430 msec male , ECG 2nd 3rd degree atrioventricular block ; current enrollment another clinical study ; previous enrollment study ; recent ( 6month ) history drug/alcohol abuse could preclude adherence protocol ; pregnant breastfeeding female ; requirement OTC and/or prescription medication , vitamins and/or herbal supplement regular basis use within 2week period prior first dose study drug administration within 10 halflives respective medication ; use known inhibitor inducer cytochrome P450 3A cytochrome P450 2C8 within 1 month prior study drug administration ; positive screen drug abuse , alcohol , cotinine ; receipt drug injection within 30 day prior study drug administration ; receipt investigational product within time period equal 10 halflives product minimum 6 week prior study drug administration ; consumption alcohol within 48 hour prior study drug administration ; consumption grapefruit , grapefruit product , star fruit , star fruit product within 72hour period prior study drug administration ; consideration investigator , reason , subject unsuitable candidate receive ABT333 ; history cardiac disease , include family history longQT syndrome unexplained sudden death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>multiple ascend dos ( MAD )</keyword>
</DOC>